Planet 13 Holdings Reports 27.6% Revenue Decline and $44M Net Loss in Q3 2025

Planet 13 Holdings Inc. reported significant financial challenges in its latest 10-Q filing for the third quarter of 2025, revealing a net revenue of $23.3 million, a decrease of 27.6% from $32.2 million in the same period last year. For the nine months ending September 30, 2025, total revenue was $78.2 million, down 9.3% from $86.1 million in 2024. The company also experienced a substantial net loss of $44.0 million for the quarter, compared to a loss of $7.4 million in the prior year, and a nine-month loss of $59.3 million versus $21.4 million in 2024. The gross profit margin fell sharply to 21.3% for the quarter, down from 51.9% a year earlier, primarily due to price compression and increased competition in the cannabis market.

The filing highlighted several operational changes, including the impact of the VidaCann acquisition, which added new revenue streams but also contributed to increased expenses. General and administrative expenses rose to $12.0 million for the quarter, down from $14.8 million in the previous year, while total expenses surged to $46.2 million, a 130.8% increase year-over-year. The company recorded an impairment loss of $29.8 million related to cultivation assets, reflecting the ongoing decline in market prices for cannabis products, particularly in the flower category.

In terms of operational metrics, Planet 13's customer counts and engagement levels have been adversely affected by a decline in tourism in Las Vegas and reduced disposable income among consumers. The company reported a decrease in customer traffic at its flagship Las Vegas superstore, which has historically been a significant revenue driver. The company is also facing challenges in its California operations, where it plans to discontinue its retail and cultivation activities to focus on more profitable markets in Nevada and Florida.

Looking ahead, Planet 13 is strategically positioning itself for long-term growth by divesting from underperforming assets and focusing on its core markets. The company has plans to enhance its product offerings and expand its retail presence in Florida, where it currently operates 33 medical dispensaries and is working on additional locations. However, the company acknowledges the need for additional financing to support its growth initiatives, given its recent history of operating losses and the uncertain regulatory landscape surrounding the cannabis industry. The management remains optimistic about future opportunities but recognizes the inherent risks and challenges in the evolving market.